

## COMMON TOXICITY CRITERIA (CTC)

Adverse Event	Grade				
	0	1	2	3	4
<b>ALLERGY/IMMUNOLOGY</b>					
Allergic reaction/ hypersensitivity (including drug fever)	none	transient rash, drug fever <38°C (<100.4°F)	urticaria, drug fever ≥38°C (≥100.4°F), and/or asymptomatic bronchospasm	symptomatic bronchospasm, requiring parenteral medication(s), with or without urticaria; allergy-related edema/angioedema	anaphylaxis
Note: Isolated urticaria, in the absence of other manifestations of an allergic or hypersensitivity reaction, is graded in the DERMATOLOGY/SKIN category.					
Allergic rhinitis (including sneezing, nasal stiffness, postnasal drip)	none	mild, not requiring treatment	moderate, requiring treatment	-	-
Autoimmune reaction	none	serologic or other evidence of autoimmune reaction but patient is asymptomatic (e.g., vitiligo), all organ function is normal and no treatment is required	evidence of autoimmune reaction involving a non- essential organ or function (e.g., hypothyroidism), requiring treatment other than immunosuppressive drugs	reversible autoimmune reaction involving function of a major organ or other adverse event (e.g., transient colitis or anemia), requiring short-term immunosuppressive treatment	autoimmune reaction causing major grade 4 organ dysfunction; progressive and irreversible reaction; long-term administration of high- dose immuno- suppressive therapy required
Also consider Hypothyroidism, Colitis, Hemoglobin, Hemolysis.					
Serum sickness	none	-	-	present	-
Urticaria is graded in the DERMATOLOGY/SKIN category if it occurs as an isolated symptom. If it occurs with other manifestations of allergic or hypersensitivity reaction, grade as Allergic reaction/hypersensitivity above.					
Vasculitis	none	mild, not requiring treatment	symptomatic, requiring medication	requiring steroids	ischemic changes or requiring amputation
Allergy/Immunology - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling
<b>AUDITORY/HEARING</b>					
Conductive hearing loss is graded as Middle ear/hearing in the AUDITORY/HEARING category.					
Earache is graded in the PAIN category.					
External auditory canal	normal	external otitis with erythema or dry desquamation	external otitis with moist desquamation	external otitis with discharge, mastoiditis	necrosis of the canal soft tissue or bone
Note: Changes associated with radiation to external ear (pinnae) are graded under Radiation dermatitis in the DERMATOLOGY/SKIN category.					

Adverse Event	Grade				
	0	1	2	3	4
Inner ear/hearing	normal	hearing loss on audiometry only	tinnitus or hearing loss, not requiring hearing aid or treatment	tinnitus or hearing loss, correctable with hearing aid or treatment	severe unilateral or bilateral hearing loss (deafness), not correctable
Middle ear/hearing	normal	serous otitis without subjective decrease in hearing	serous otitis or infection requiring medical intervention; subjective decrease in hearing; rupture of tympanic membrane with discharge	otitis with discharge, mastoiditis or conductive hearing loss	necrosis of the canal soft tissue or bone
Auditory/Hearing - Other (Specify, _____)	normal	mild	moderate	severe	life-threatening or disabling
<b>BLOOD/BONE MARROW</b>					
Bone marrow cellularity	normal for age	mildly hypocellular or $\leq 25\%$ reduction from normal cellularity for age	moderately hypocellular or $>25 - \leq 50\%$ reduction from normal cellularity for age or $>2$ but $<4$ weeks to recovery of normal bone marrow cellularity	severely hypocellular or $>50 - \leq 75\%$ reduction in cellularity for age or 4 - 6 weeks to recovery of normal bone marrow cellularity	aplasia or $>6$ weeks to recovery of normal bone marrow cellularity
Normal ranges:					
<i>children (<math>\leq 18</math> years)</i>	<b>90% cellularity average</b>				
younger adults (19-59)	60 - 70% cellularity average				
older adults ( $\geq 60$ years)	50% cellularity average				
Note: Grade Bone marrow cellularity only for changes related to treatment not disease.					
CD4 count	WNL	$<LLN - 500/mm^3$	200 - $<500/mm^3$	50 - $<200/mm^3$	$<50/mm^3$
Haptoglobin	normal	decreased	-	absent	-
Hemoglobin (Hgb)	WNL	$<LLN - 10.0$ g/dL $<LLN - 100$ g/L $<LLN - 6.2$ mmol/L	8.0 - $<10.0$ g/dL 80 - $<100$ g/L 4.9 - $<6.2$ mmol/L	6.5 - $<8.0$ g/dL 65 - $<80$ g/L 4.0 - $<4.9$ mmol/L	$<6.5$ g/dL $<65$ g/L $<4.0$ mmol/L
<b>For leukemia studies or bone marrow infiltrative/myelophthisic processes, if specified in the protocol.</b>	<b>WNL</b>	<b>10 - <math>&lt;25\%</math> decrease from pretreatment</b>	<b>25 - <math>&lt;50\%</math> decrease from pretreatment</b>	<b>50 - <math>&lt;75\%</math> decrease from pretreatment</b>	<b><math>\geq 75\%</math> decrease from pretreatment</b>
Hemolysis (e.g., immune hemolytic anemia, drug-related hemolysis, other)	none	only laboratory evidence of hemolysis [e.g., direct antiglobulin test (DAT, Coombs') schistocytes]	evidence of red cell destruction and $\geq 2$ gm decrease in hemoglobin, no transfusion	requiring transfusion and/or medical intervention (e.g., steroids)	catastrophic consequences of hemolysis (e.g., renal failure, hypotension, bronchospasm, emergency splenectomy)
Also consider Haptoglobin, Hemoglobin.					

Adverse Event	Grade				
	0	1	2	3	4
Leukocytes (total WBC)	WNL	<LLN - $3.0 \times 10^9$ /L <LLN - 3000/mm <sup>3</sup>	$\geq 2.0$ - $<3.0 \times 10^9$ /L $\geq 2000$ - $<3000$ /mm <sup>3</sup>	$\geq 1.0$ - $<2.0 \times 10^9$ /L $\geq 1000$ - $<2000$ /mm <sup>3</sup>	$<1.0 \times 10^9$ /L <1000/mm <sup>3</sup>
<b>For BMT studies, if specified in the protocol.</b>	<b>WNL</b>	<b><math>\geq 2.0</math> - <math>&lt;3.0 \times 10^9</math> /L <math>\geq 2000</math> - <math>&lt;3000</math>/mm<sup>3</sup></b>	<b><math>\geq 1.0</math> - <math>&lt;2.0 \times 10^9</math> /L <math>\geq 1000</math> - <math>&lt;2000</math>/mm<sup>3</sup></b>	<b><math>\geq 0.5</math> - <math>&lt;1.0 \times 10^9</math> /L <math>\geq 500</math> - <math>&lt;1000</math>/mm<sup>3</sup></b>	<b><math>&lt;0.5 \times 10^9</math> /L <math>&lt;500</math>/mm<sup>3</sup></b>
<i>For pediatric BMT studies (using age, race and sex normal values), if specified in the protocol.</i>		<i><math>\geq 75</math> - <math>&lt;100\%</math> LLN</i>	<i><math>\geq 50</math> - <math>&lt;75\%</math> LLN</i>	<i><math>\geq 25</math> - <math>50\%</math> LLN</i>	<i><math>&lt;25\%</math> LLN</i>
Lymphopenia	WNL	<LLN - $1.0 \times 10^9$ /L <LLN - 1000/mm <sup>3</sup>	$\geq 0.5$ - $<1.0 \times 10^9$ /L $\geq 500$ - $<1000$ /mm <sup>3</sup>	$<0.5 \times 10^9$ /L <500/mm <sup>3</sup>	-
<i>For pediatric BMT studies (using age, race and sex normal values), if specified in the protocol.</i>		<i><math>\geq 75</math> - <math>&lt;100\%</math>LLN</i>	<i><math>\geq 50</math> - <math>&lt;75\%</math>LLN</i>	<i><math>\geq 25</math> - <math>&lt;50\%</math>LLN</i>	<i><math>&lt;25\%</math>LLN</i>
Neutrophils/granulocytes (ANC/AGC)	WNL	$\geq 1.5$ - $<2.0 \times 10^9$ /L $\geq 1500$ - $<2000$ /mm <sup>3</sup>	$\geq 1.0$ - $<1.5 \times 10^9$ /L $\geq 1000$ - $<1500$ /mm <sup>3</sup>	$\geq 0.5$ - $<1.0 \times 10^9$ /L $\geq 500$ - $<1000$ /mm <sup>3</sup>	$<0.5 \times 10^9$ /L <500/mm <sup>3</sup>
<b>For BMT studies, if specified in the protocol.</b>	<b>WNL</b>	<b><math>\geq 1.0</math> - <math>&lt;1.5 \times 10^9</math> /L <math>\geq 1000</math> - <math>&lt;1500</math>/mm<sup>3</sup></b>	<b><math>\geq 0.5</math> - <math>&lt;1.0 \times 10^9</math> /L <math>\geq 500</math> - <math>&lt;1000</math>/mm<sup>3</sup></b>	<b><math>\geq 0.1</math> - <math>&lt;0.5 \times 10^9</math> /L <math>\geq 100</math> - <math>&lt;500</math>/mm<sup>3</sup></b>	<b><math>&lt;0.1 \times 10^9</math> /L <math>&lt;100</math>/mm<sup>3</sup></b>
<b>For leukemia studies or bone marrow infiltrative/myelophthisic process, if specified in the protocol.</b>	<b>WNL</b>	<b>10 - <math>&lt;25\%</math> decrease from baseline</b>	<b>25 - <math>&lt;50\%</math> decrease from baseline</b>	<b>50 - <math>&lt;75\%</math> decrease from baseline</b>	<b><math>\geq 75\%</math> decrease from baseline</b>
Platelets	WNL	<LLN - $75.0 \times 10^9$ /L <LLN - 75,000/mm <sup>3</sup>	$\geq 50.0$ - $<75.0 \times 10^9$ /L $\geq 50,000$ - $<75,000$ /mm <sup>3</sup>	$\geq 10.0$ - $<50.0 \times 10^9$ /L $\geq 10,000$ - $<50,000$ /mm <sup>3</sup>	$<10.0 \times 10^9$ /L <10,000/mm <sup>3</sup>
<b>For BMT studies, if specified in the protocol.</b>	<b>WNL</b>	<b><math>\geq 50.0</math> - <math>&lt;75.0 \times 10^9</math> /L <math>\geq 50,000</math> - <math>&lt;75,000</math>/mm<sup>3</sup></b>	<b><math>\geq 20.0</math> - <math>&lt;50.0 \times 10^9</math> /L <math>\geq 20,000</math> - <math>&lt;50,000</math>/mm<sup>3</sup></b>	<b><math>\geq 10.0</math> - <math>&lt;20.0 \times 10^9</math> /L <math>\geq 10,000</math> - <math>&lt;20,000</math>/mm<sup>3</sup></b>	<b><math>&lt;10.0 \times 10^9</math> /L <math>&lt;10,000</math>/mm<sup>3</sup></b>
<b>For leukemia studies or bone marrow infiltrative/myelophthisic process, if specified in the protocol.</b>	<b>WNL</b>	<b>10 - <math>&lt;25\%</math> decrease from baseline</b>	<b>25 - <math>&lt;50\%</math> decrease from baseline</b>	<b>50 - <math>&lt;75\%</math> decrease from baseline</b>	<b><math>\geq 75\%</math> decrease from baseline</b>
Transfusion: Platelets	none	-	-	yes	platelet transfusions and other measures required to improve platelet increment; platelet transfusion refractoriness associated with life-threatening bleeding. (e.g., HLA or cross matched platelet transfusions)
<b>For BMT studies, if specified in the protocol.</b>	<b>none</b>	<b>1 platelet transfusion in 24 hours</b>	<b>2 platelet transfusions in 24 hours</b>	<b><math>\geq 3</math> platelet transfusions in 24 hours</b>	<b>platelet transfusions and other measures required to improve platelet increment; platelet transfusion refractoriness associated with life-threatening bleeding. (e.g., HLA or cross matched platelet transfusions)</b>

Also consider Platelets.

Adverse Event	Grade				
	0	1	2	3	4
Transfusion: pRBCs	none	-	-	yes	-
<b>For BMT studies, if specified in the protocol.</b>	<b>none</b>	<b>≤2 u pRBC in 24 hours elective or planned</b>	<b>3 u pRBC in 24 hours elective or planned</b>	<b>≥4 u pRBC in 24 hours</b>	<b>hemorrhage or hemolysis associated with life-threatening anemia; medical intervention required to improve hemoglobin</b>
<i>For pediatric BMT studies, if specified in the protocol.</i>	<i>none</i>	<i>≤15mL/kg in 24 hours elective or planned</i>	<i>&gt;15 - ≤30mL/kg in 24 hours elective or planned</i>	<i>&gt;30mL/kg in 24 hours</i>	<i>hemorrhage or hemolysis associated with life-threatening anemia; medical intervention required to improve hemoglobin</i>
Also consider Hemoglobin.					
Blood/Bone Marrow - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling
<b>CARDIOVASCULAR (ARRHYTHMIA)</b>					
Conduction abnormality/ Atrioventricular heart block	none	asymptomatic, not requiring treatment (e.g., Mobitz type I second-degree AV block, Wenckebach)	symptomatic, but not requiring treatment	symptomatic and requiring treatment (e.g., Mobitz type II second-degree AV block, third-degree AV block)	life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock)
Nodal/junctional arrhythmia/dysrhythmia	none	asymptomatic, not requiring treatment	symptomatic, but not requiring treatment	symptomatic and requiring treatment	life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock)
Palpitations	none	present	-	-	-
Note: Grade palpitations <u>only</u> in the absence of a documented arrhythmia.					
Prolonged QTc interval (QTc >0.48 seconds)	none	asymptomatic, not requiring treatment	symptomatic, but not requiring treatment	symptomatic and requiring treatment	life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock)
Sinus bradycardia	none	asymptomatic, not requiring treatment	symptomatic, but not requiring treatment	symptomatic and requiring treatment	life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock)
Sinus tachycardia	none	asymptomatic, not requiring treatment	symptomatic, but not requiring treatment	symptomatic and requiring treatment of underlying cause	-
Supraventricular arrhythmias (SVT/atrial fibrillation/flutter)	none	asymptomatic, not requiring treatment	symptomatic, but not requiring treatment	symptomatic and requiring treatment	life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock)
Syncope (fainting) is graded in the NEUROLOGY category.					
Vasovagal episode	none	-	present without loss of consciousness	present with loss of consciousness	-

Adverse Event	Grade				
	0	1	2	3	4
Ventricular arrhythmia (PVCs/bigeminy/trigeminy/ventricular tachycardia)	none	asymptomatic, not requiring treatment	symptomatic, but not requiring treatment	symptomatic and requiring treatment	life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock)
Cardiovascular/ Arrhythmia - Other (Specify, _____)	none	asymptomatic, not requiring treatment	symptomatic, but not requiring treatment	symptomatic, and requiring treatment of underlying cause	life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock)
<b>CARDIOVASCULAR (GENERAL)</b>					
Acute vascular leak syndrome	absent	-	symptomatic, but not requiring fluid support	respiratory compromise or requiring fluids	life-threatening; requiring pressor support and/or ventilatory support
Cardiac-ischemia/infarction	none	non-specific T - wave flattening or changes	asymptomatic, ST - and T - wave changes suggesting ischemia	angina without evidence of infarction	acute myocardial infarction
Cardiac left ventricular function	normal	asymptomatic decline of resting ejection fraction of $\geq 10\%$ but $< 20\%$ of baseline value; shortening fraction $\geq 24\%$ but $< 30\%$	asymptomatic but resting ejection fraction below LLN for laboratory or decline of resting ejection fraction $\geq 20\%$ of baseline value; $< 24\%$ shortening fraction	CHF responsive to treatment	severe or refractory CHF or requiring intubation
CNS cerebrovascular ischemia is graded in the NEUROLOGY category.					
Cardiac troponin I (cTnI)	normal	-	-	levels consistent with unstable angina as defined by the manufacturer	levels consistent with myocardial infarction as defined by the manufacturer
Cardiac troponin T (cTnT)	normal	$\geq 0.03$ - $< 0.05$ ng/mL	$\geq 0.05$ - $< 0.1$ ng/mL	$\geq 0.1$ - $< 0.2$ ng/mL	$\geq 0.2$ ng/mL
Edema	none	asymptomatic, not requiring therapy	symptomatic, requiring therapy	symptomatic edema limiting function and unresponsive to therapy or requiring drug discontinuation	anasarca (severe generalized edema)
Hypertension	none	asymptomatic, transient increase by $> 20$ mmHg (diastolic) or to $> 150/100^*$ if previously WNL; not requiring treatment	recurrent or persistent or symptomatic increase by $> 20$ mmHg (diastolic) or to $> 150/100^*$ if previously WNL; not requiring treatment	requiring therapy or more intensive therapy than previously	hypertensive crisis
<i>*Note: For pediatric patients, use age and sex appropriate normal values <math>&gt; 95</math>th percentile ULN.</i>					

Adverse Event	Grade				
	0	1	2	3	4
Hypotension	none	changes, but not requiring therapy (including transient orthostatic hypotension)	requiring brief fluid replacement or other therapy but not hospitalization; no physiologic consequences	requiring therapy and sustained medical attention, but resolves without persisting physiologic consequences	shock (associated with acidemia and impairing vital organ function due to tissue hypoperfusion)
<p>Also consider Syncope (fainting).</p> <p>Notes: Angina or MI is graded as Cardiac-ischemia/infarction in the CARDIOVASCULAR (GENERAL) category.</p> <p><i>For pediatric patients, systolic BP 65 mmHg or less in infants up to 1 year old and 70 mmHg or less in children older than 1 year of age, use two successive or three measurements in 24 hours.</i></p>					
Myocarditis	none	-	-	CHF responsive to treatment	severe or refractory CHF
Operative injury of vein/artery	none	primary suture repair for injury, but not requiring transfusion	primary suture repair for injury, requiring transfusion	vascular occlusion requiring surgery or bypass for injury	myocardial infarction; resection of organ (e.g., bowel, limb)
Pericardial effusion/pericarditis	none	asymptomatic effusion, not requiring treatment	pericarditis (rub, ECG changes, and/or chest pain)	with physiologic consequences	tamponade (drainage or pericardial window required)
Peripheral arterial ischemia	none	-	brief episode of ischemia managed non-surgically and without permanent deficit	requiring surgical intervention	life-threatening or with permanent functional deficit (e.g., amputation)
Phlebitis (superficial)	none	-	present	-	-
<p>Notes: Injection site reaction is graded in the DERMATOLOGY/SKIN category.</p> <p>Thrombosis/embolism is graded in the CARDIOVASCULAR (GENERAL) category.</p>					
Syncope (fainting) is graded in the NEUROLOGY category.					
Thrombosis/embolism	none	-	deep vein thrombosis, not requiring anticoagulant	deep vein thrombosis, requiring anticoagulant therapy	embolic event including pulmonary embolism
Vein/artery operative injury is graded as Operative injury of vein/artery in the CARDIOVASCULAR (GENERAL) category.					
Visceral arterial ischemia (non-myocardial)	none	-	brief episode of ischemia managed non-surgically and without permanent deficit	requiring surgical intervention	life-threatening or with permanent functional deficit (e.g., resection of ileum)
Cardiovascular/General - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling

Adverse Event	Grade				
	0	1	2	3	4
<b>COAGULATION</b>					
Note: See the HEMORRHAGE category for grading the severity of bleeding events.					
DIC (disseminated intravascular coagulation)  Also consider Platelets.  Note: Must have increased fibrin split products or D-dimer in order to grade as DIC.	absent	-	-	laboratory findings present with <u>no</u> bleeding	laboratory findings <u>and</u> bleeding
Fibrinogen  <b>For leukemia studies or bone marrow infiltrative/myelophthisic process, if specified in the protocol.</b>	WNL  WNL	≥0.75 - <1.0 x LLN  <20% decrease from pretreatment value or LLN	≥0.5 - <0.75 x LLN  ≥20 - <40% decrease from pretreatment value or LLN	≥0.25 - <0.5 x LLN  ≥40 - <70% decrease from pretreatment value or LLN	<0.25 x LLN  <50 mg
Partial thromboplastin time (PTT)	WNL	>ULN - ≤1.5 x ULN	>1.5 - ≤2 x ULN	>2 x ULN	-
Phlebitis is graded in the CARDIOVASCULAR (GENERAL) category.					
Prothrombin time (PT)	WNL	>ULN - ≤1.5 x ULN	>1.5 - ≤2 x ULN	>2 x ULN	-
Thrombosis/embolism is graded in the CARDIOVASCULAR (GENERAL) category.					
Thrombotic microangiopathy (e.g., thrombotic thrombocytopenic purpura/TTP or hemolytic uremic syndrome/HUS)  <b>For BMT studies, if specified in the protocol.</b>	absent  -	-  evidence of RBC destruction (schistocytosis) without clinical consequences	-  evidence of RBC destruction with elevated creatinine (≤3 x ULN)	laboratory findings present without clinical consequences  evidence of RBC destruction with creatinine (>3 x ULN) not requiring dialysis	laboratory findings and clinical consequences, (e.g., CNS hemorrhage/bleeding or thrombosis/embolism or renal failure) requiring therapeutic intervention  evidence of RBC destruction with renal failure requiring dialysis and/or encephalopathy
Also consider Hemoglobin, Platelets, Creatinine. Note: Must have microangiopathic changes on blood smear (e.g., schistocytes, helmet cells, red cell fragments).					
Coagulation - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling
<b>CONSTITUTIONAL SYMPTOMS</b>					
Fatigue (lethargy, malaise, asthenia)	none	increased fatigue over baseline, but not altering normal activities	moderate (e.g., decrease in performance status by 1 ECOG level <u>or</u> 20% Karnofsky or <i>Lansky</i> ) <u>or</u> causing difficulty performing some activities	severe (e.g., decrease in performance status by ≥2 ECOG levels <u>or</u> 40% Karnofsky or <i>Lansky</i> ) <u>or</u> loss of ability to perform some activities	bedridden or disabling
Note: See Appendix III for performance status scales.					

Adverse Event	Grade				
	0	1	2	3	4
Fever (in the absence of neutropenia, where neutropenia is defined as AGC <1.0 x 10 <sup>9</sup> /L)	none	38.0 - 39.0°C (100.4 - 102.2°F)	39.1 - 40.0°C (102.3 - 104.0°F)	>40.0°C (>104.0°F) for <24hrs	>40.0°C (>104.0°F) for >24hrs
Also consider Allergic reaction/hypersensitivity.					
Note: The temperature measurements listed above are oral or tympanic.					
Hot flashes/flushes are graded in the ENDOCRINE category.					
Rigors, chills	none	mild, requiring symptomatic treatment (e.g., blanket) or non-narcotic medication	severe and/or prolonged, requiring narcotic medication	not responsive to narcotic medication	-
Sweating (diaphoresis)	normal	mild and occasional	frequent or drenching	-	-
Weight gain	<5%	5 - <10%	10 - <20%	≥20%	-
Also consider Ascites, Edema, Pleural effusion (non-malignant).					
<b>Weight gain associated with Venous Occlusive Disease (VOD) for BMT studies, if specified in the protocol.</b>	<b>&lt;2%</b>	<b>≥2 - &lt;5%</b>	<b>≥5 - &lt;10%</b>	<b>≥10% or as ascites</b>	<b>≥10% or fluid retention resulting in pulmonary failure</b>
<b>Also consider Ascites, Edema, Pleural effusion (non-malignant).</b>					
Weight loss	<5%	5 - <10%	10 - <20%	≥20%	-
Also consider Vomiting, Dehydration, Diarrhea.					
Constitutional Symptoms - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling
<b>DERMATOLOGY/SKIN</b>					
Alopecia	normal	mild hair loss	pronounced hair loss	-	-
Bruising (in absence of grade 3 or 4 thrombocytopenia)	none	localized or in dependent area	generalized	-	-
Note: Bruising <u>resulting from grade 3 or 4 thrombocytopenia</u> is graded as Petechiae/purpura <u>and</u> Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia in the HEMORRHAGE category, <u>not</u> in the DERMATOLOGY/SKIN category.					
Dry skin	normal	controlled with emollients	not controlled with emollients	-	-
Erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)	absent	-	scattered, but not generalized eruption	severe or requiring IV fluids (e.g., generalized rash or painful stomatitis)	life-threatening (e.g., exfoliative or ulcerating dermatitis or requiring enteral or parenteral nutritional support)
Flushing	absent	present	-	-	-
Hand-foot skin reaction	none	skin changes or dermatitis without pain (e.g., erythema, peeling)	skin changes with pain, not interfering with function	skin changes with pain, interfering with function	-
Injection site reaction	none	pain or itching or erythema	pain or swelling, with inflammation or phlebitis	ulceration or necrosis that is severe or prolonged, or requiring surgery	-



Adverse Event	Grade				
	0	1	2	3	4
Nail changes	normal	discoloration or ridging (koilonychia) or pitting	partial or complete loss of nail(s) or pain in nailbeds	-	-
Petechiae is graded in the HEMORRHAGE category.					
Photosensitivity	none	painless erythema	painful erythema	erythema with desquamation	-
Pigmentation changes (e.g., vitiligo)	none	localized pigmentation changes	generalized pigmentation changes	-	-
Pruritus	none	mild or localized, relieved spontaneously or by local measures	intense or widespread, relieved spontaneously or by systemic measures	intense or widespread and poorly controlled despite treatment	-
Purpura is graded in the HEMORRHAGE category.					
<b>Radiation dermatitis</b>	<b>none</b>	<b>faint erythema or dry desquamation</b>	<b>moderate to brisk erythema or a patchy moist desquamation, mostly confined to skin folds and creases; moderate edema</b>	<b>confluent moist desquamation <math>\geq 1.5</math> cm diameter and not confined to skin folds; pitting edema</b>	<b>skin necrosis or ulceration of full thickness dermis; may include bleeding not induced by minor trauma or abrasion</b>
<b>Note: Pain associated with radiation dermatitis is graded separately in the PAIN category as Pain due to radiation.</b>					
<b>Radiation recall reaction (reaction following chemotherapy in the absence of additional radiation therapy that occurs in a previous radiation port)</b>	<b>none</b>	<b>faint erythema or dry desquamation</b>	<b>moderate to brisk erythema or a patchy moist desquamation, mostly confined to skin folds and creases; moderate edema</b>	<b>confluent moist desquamation <math>\geq 1.5</math> cm diameter and not confined to skin folds; pitting edema</b>	<b>skin necrosis or ulceration of full thickness dermis; may include bleeding not induced by minor trauma or abrasion</b>
Rash/desquamation	none	macular or papular eruption or erythema without associated symptoms	macular or papular eruption or erythema with pruritus or other associated symptoms covering <50% of body surface or localized desquamation or other lesions covering <50% of body surface area	symptomatic generalized erythroderma or macular, papular or vesicular eruption or desquamation covering $\geq 50\%$ of body surface area	generalized exfoliative dermatitis or ulcerative dermatitis
Also consider Allergic reaction/hypersensitivity.					
Note: Stevens-Johnson syndrome is graded separately as Erythema multiforme in the DERMATOLOGY/SKIN category.					
<b>Rash/dermatitis associated with high-dose chemotherapy or BMT studies.</b>	<b>none</b>	<b>faint erythema or dry desquamation</b>	<b>moderate to brisk erythema or a patchy moist desquamation, mostly confined to skin folds and creases; moderate edema</b>	<b>confluent moist desquamation <math>\geq 1.5</math> cm diameter and not confined to skin folds; pitting edema</b>	<b>skin necrosis or ulceration of full thickness dermis; may include spontaneous bleeding not induced by minor trauma or abrasion</b>
<b>Rash/desquamation associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol.</b>	<b>None</b>	<b>macular or papular eruption or erythema covering &lt;25% of body surface area without associated symptoms</b>	<b>macular or papular eruption or erythema with pruritus or other associated symptoms covering <math>\geq 25</math> - &lt;50% of body surface or localized esquamation or other lesions covering <math>\geq 25</math> - &lt;50% of body surface area</b>	<b>symptomatic generalized erythroderma or symptomatic macular, papular or vesicular eruption, with bullous formation, or desquamation covering <math>\geq 50\%</math> of body surface area</b>	<b>generalized exfoliative dermatitis or ulcerative dermatitis or bullous formation</b>
Also consider Allergic reaction/hypersensitivity.					
<b>Note: Stevens-Johnson syndrome is graded separately as Erythema multiforme in the DERMATOLOGY/SKIN category.</b>					

Adverse Event	Grade				
	0	1	2	3	4
Urticaria (hives, welts, wheals)	none	requiring no medication	requiring PO or topical treatment or IV medication or steroids for <24 hours	requiring IV medication or steroids for ≥24 hours	-
Wound-infectious	none	cellulitis	superficial infection	infection requiring IV antibiotics	necrotizing fasciitis
Wound-non-infectious	none	incisional separation	incisional hernia	fascial disruption without evisceration	fascial disruption with evisceration
Dermatology/Skin - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling
<b>ENDOCRINE</b>					
Cushingoid appearance (e.g., moon face, buffalo hump, centripetal obesity, cutaneous striae) Also consider Hyperglycemia, Hypokalemia.	absent	-	present	-	-
Feminization of male	absent	-	-	present	-
Gynecomastia	none	mild	pronounced or painful	pronounced or painful and requiring surgery	-
Hot flashes/flushes	none	mild or no more than 1 per day	moderate and greater than 1 per day	-	-
Hypothyroidism	absent	asymptomatic, TSH elevated, no therapy given	symptomatic or thyroid replacement treatment given	patient hospitalized for manifestations of hypothyroidism	myxedema coma
Masculinization of female	absent	-	-	present	-
SIADH (syndrome of inappropriate antidiuretic hormone)	absent	-	-	present	-
Endocrine - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling
<b>GASTROINTESTINAL</b>					
Amylase is graded in the METABOLIC/LABORATORY category.					
Anorexia	none	loss of appetite	oral intake significantly decreased	requiring IV fluids	requiring feeding tube or parenteral nutrition
Ascites (non-malignant)	none	asymptomatic	symptomatic, requiring diuretics	symptomatic, requiring therapeutic paracentesis	life-threatening physiologic consequences
Colitis	none	-	abdominal pain with mucus and/or blood in stool	abdominal pain, fever, change in bowel habits with ileus or peritoneal signs, and radiographic or biopsy documentation	perforation or requiring surgery or toxic megacolon
Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, Melena/GI bleeding, Rectal bleeding/hematochezia, Hypotension.					
Constipation	none	requiring stool softener or dietary modification	requiring laxatives	obstipation requiring manual evacuation or enema	obstruction or toxic megacolon

Adverse Event	Grade				
	0	1	2	3	4
Dehydration	none	dry mucous membranes and/or diminished skin turgor	requiring IV fluid replacement (brief)	requiring IV fluid replacement (sustained)	physiologic consequences requiring intensive care; hemodynamic collapse
Also consider Diarrhea, Vomiting, Stomatitis/pharyngitis (oral/pharyngeal mucositis), Hypotension.					
Diarrhea patients without colostomy:	none	increase of <4 stools/day over pretreatment	increase of 4-6 stools/day, or nocturnal stools	increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration	physiologic consequences requiring intensive care; or hemodynamic collapse
patients with a colostomy:	none	mild increase in loose, watery colostomy output compared with pretreatment	moderate increase in loose, watery colostomy output compared with pretreatment, but not interfering with normal activity	severe increase in loose, watery colostomy output compared with pretreatment, interfering with normal activity	physiologic consequences, requiring intensive care; or hemodynamic collapse
<b>Diarrhea associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol.</b>	<b>None</b>	<b>&gt;500 - ≤1000mL of diarrhea/day</b>	<b>&gt;1000 - ≤1500mL of diarrhea/day</b>	<b>&gt;1500mL of diarrhea/day</b>	<b>severe abdominal pain with or without ileus</b>
<i>For pediatric BMT studies, if specified in the protocol.</i>		<i>&gt;5 - ≤10 mL/kg of diarrhea/day</i>	<i>&gt;10 - ≤15 mL/kg of diarrhea/day</i>	<i>&gt;15 mL/kg of diarrhea/day</i>	-
Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, Pain, Dehydration, Hypotension.					
Duodenal ulcer (requires radiographic or endoscopic documentation)	none	-	requiring medical management or non-surgical treatment	uncontrolled by outpatient medical management; requiring hospitalization	perforation or bleeding, requiring emergency surgery
Dyspepsia/heartburn	none	mild	moderate	severe	-
Dysphagia, esophagitis, odynophagia (painful swallowing)	none	mild dysphagia, but can eat regular diet	dysphagia, requiring predominantly pureed, soft, or liquid diet	dysphagia, requiring IV hydration	complete obstruction (cannot swallow saliva) requiring enteral or parenteral nutritional support, or perforation
Note: If the adverse event is radiation-related, grade either under Dysphagia-esophageal related to radiation or Dysphagia-pharyngeal related to radiation.					
<b><u>Dysphagia-esophageal</u> related to radiation</b>	<b>none</b>	<b>mild dysphagia, but can eat regular diet</b>	<b>dysphagia, requiring predominantly pureed, soft, or liquid diet</b>	<b>Dysphagia, requiring feeding tube, IV hydration or hyperalimentation</b>	<b>complete obstruction (cannot swallow saliva); ulceration with bleeding not induced by minor trauma or abrasion or perforation</b>
<b>Also consider Pain due to radiation, Mucositis due to radiation.</b>					
<b>Note: Fistula is graded separately as Fistula-esophageal.</b>					
<b><u>Dysphagia-pharyngeal</u> related to radiation</b>	<b>none</b>	<b>mild dysphagia, but can eat regular diet</b>	<b>dysphagia, requiring predominantly pureed, soft, or liquid diet</b>	<b>dysphagia, requiring feeding tube, IV hydration or hyperalimentation</b>	<b>complete obstruction (cannot swallow saliva); ulceration with bleeding not induced by minor trauma or abrasion or perforation</b>
<b>Also consider Pain due to radiation, Mucositis due to radiation.</b>					
<b>Note: Fistula is graded separately as Fistula-pharyngeal.</b>					
Fistula-esophageal	none	-	-	present	requiring surgery
Fistula-intestinal	none	-	-	present	requiring surgery

Adverse Event	Grade				
	0	1	2	3	4
Fistula-pharyngeal	none	-	-	present	requiring surgery
Fistula-rectal/anal	none	-	-	present	requiring surgery
Flatulence	none	mild	moderate	-	-
Gastric ulcer (requires radiographic or endoscopic documentation)	none	-	requiring medical management or non- surgical treatment	bleeding without perforation, uncon- trolled by outpatient medical management; requiring hospitalization or surgery	perforation or bleeding, requiring emergency surgery
Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia.					
Gastritis	none	-	requiring medical management or non- surgical treatment	uncontrolled by out- patient medical management; requiring hospitalization or surgery	life-threatening bleeding, requiring emergency surgery
Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia.					
Hematemesis is graded in the HEMORRHAGE category.					
Hematochezia is graded in the HEMORRHAGE category as Rectal bleeding/hematochezia.					
Ileus (or neuroconstipation)	none	-	intermittent, not requiring intervention	requiring non-surgical intervention	requiring surgery
Mouth dryness	normal	mild	moderate	-	-
Mucositis	Notes: Mucositis <u>not due to radiation</u> is graded in the GASTROINTESTINAL category for specific sites: Colitis, Esophagitis, Gastritis, Stomatitis/pharyngitis (oral/pharyngeal mucositis), and Typhlitis; or the RENAL/GENITOURINARY category for Vaginitis.  Radiation-related mucositis is graded as Mucositis due to radiation.				
<b>Mucositis due to radiation</b>	<b>none</b>	<b>erythema of the mucosa</b>	<b>patchy pseudomembra-nous reaction (patches generally ≤1.5 cm in diameter and non- contiguous)</b>	<b>confluent pseudomem- branous reaction (contiguous patches generally &gt;1.5 cm in diameter)</b>	<b>necrosis or deep ulceration; may include bleeding not induced by minor trauma or abrasion</b>
<b>Also consider Pain due to radiation.</b>					
<b>Notes: Grade radiation mucositis of the larynx here.</b>					
<b>Dysphagia related to radiation is also graded as <u>either</u> Dysphagia-esophageal related to radiation <u>or</u> Dysphagia-pharyngeal related to radiation, depending on the site of treatment.</b>					
Nausea	none	able to eat	oral intake significantly decreased	no significant intake, requiring IV fluids	-
Pancreatitis	none	-	-	abdominal pain with pancreatic enzyme elevation	complicated by shock (acute circulatory failure)
Also consider Hypotension.					
Note: Amylase is graded in the METABOLIC/LABORATORY category.					
Pharyngitis is graded in the GASTROINTESTINAL category as Stomatitis/pharyngitis (oral/pharyngeal mucositis).					

Adverse Event	Grade				
	0	1	2	3	4
Proctitis	none	increased stool frequency, occasional blood-streaked stools or rectal discomfort (including hemorrhoids) not requiring medication	increased stool frequency, bleeding, mucus discharge, or rectal discomfort requiring medication; anal fissure	increased stool frequency/diarrhea requiring parenteral support; rectal bleeding requiring transfusion; or persistent mucus discharge, necessitating pads	perforation, bleeding or necrosis or other life-threatening complication requiring surgical intervention (e.g., colostomy)
<p>Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, Pain due to radiation.</p> <p>Notes: Fistula is graded separately as Fistula-rectal/anal.</p> <p>Proctitis occurring more than 90 days after the start of radiation therapy is graded in the RTOG/EORTC Late Radiation Morbidity Scoring Scheme. (See Appendix IV)</p>					
Salivary gland changes	none	slightly thickened saliva; may have slightly altered taste (e.g., metallic); additional fluids may be required	thick, ropy, sticky saliva; markedly altered taste; alteration in diet required	-	acute salivary gland necrosis
Sense of smell	normal	slightly altered	markedly altered	-	-
Stomatitis/pharyngitis (oral/pharyngeal mucositis)	none	painless ulcers, erythema, or mild soreness in the absence of lesions	painful erythema, edema, or ulcers, but can eat or swallow	painful erythema, edema, or ulcers requiring IV hydration	severe ulceration or requires parenteral or enteral nutritional support or prophylactic intubation
<b>For BMT studies, if specified in the protocol.</b>	<b>none</b>	<b>painless ulcers, erythema, or mild soreness in the absence of lesions</b>	<b>painful erythema, edema or ulcers but can swallow</b>	<b>painful erythema, edema, or ulcers preventing swallowing or requiring hydration or parenteral (or enteral) nutritional support</b>	<b>severe ulceration requiring prophylactic intubation or resulting in documented aspiration pneumonia</b>
<p>Note: Radiation-related mucositis is graded as Mucositis due to radiation.</p>					
Taste disturbance (dysgeusia)	normal	slightly altered	markedly altered	-	-
Typhlitis (inflammation of the cecum)	none	-	-	abdominal pain, diarrhea, fever, and radiographic or biopsy documentation	perforation, bleeding or necrosis or other life-threatening complication requiring surgical intervention (e.g., colostomy)
<p>Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, Hypotension, Febrile neutropenia.</p>					
Vomiting	none	1 episode in 24 hours over pretreatment	2-5 episodes in 24 hours over pretreatment	≥6 episodes in 24 hours over pretreatment; or need for IV fluids	requiring parenteral nutrition; or physiologic consequences requiring intensive care; hemodynamic collapse
<p>Also consider Dehydration.</p>					
<p>Weight gain is graded in the CONSTITUTIONAL SYMPTOMS category.</p>					
<p>Weight loss is graded in the CONSTITUTIONAL SYMPTOMS category.</p>					
Gastrointestinal - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling

Adverse Event	Grade				
	0	1	2	3	4
<b>HEMORRHAGE</b>					
<p>Notes: Transfusion in this section refers to pRBC infusion.</p> <p>For <u>any</u> bleeding with grade 3 or 4 platelets (&lt;50,000), <u>always</u> grade Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia. Also consider Platelets, Transfusion: pRBCs, and Transfusion: platelets in addition to grading severity by grading the site or type of bleeding.</p> <p>If the site or type of Hemorrhage/bleeding is listed, also use the grading that incorporates the site of bleeding: CNS Hemorrhage/bleeding, Hematuria, Hematemesis, Hemoptysis, Hemorrhage/bleeding with surgery, Melena/lower GI bleeding, Petechiae/purpura (Hemorrhage/bleeding into skin), Rectal bleeding/hematochezia, Vaginal bleeding.</p> <p>If the platelet count is <math>\geq 50,000</math> and the site or type of bleeding is listed, grade the specific site. If the site or type is <u>not</u> listed and the platelet count is <math>\geq 50,000</math>, grade Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia and specify the site or type in the OTHER category.</p>					
Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia	none	mild without transfusion		requiring transfusion	catastrophic bleeding, requiring major non-elective intervention
<p>Also consider Platelets, Hemoglobin, Transfusion: platelets, Transfusion: pRBCs, site or type of bleeding. If the site is not listed, grade as Hemorrhage-Other (Specify site, _____).</p> <p>Note: This adverse event must be graded for any bleeding with grade 3 or 4 thrombocytopenia.</p>					
Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia	none	mild without transfusion		requiring transfusion	catastrophic bleeding requiring major non-elective intervention
<p>Also consider Platelets, Hemoglobin, Transfusion: platelets, Transfusion: pRBCs, Hemorrhage - Other (Specify site, _____).</p> <p>Note: Bleeding in the absence of grade 3 or 4 thrombocytopenia is graded here only if the specific site or type of bleeding is not listed elsewhere in the HEMORRHAGE category. Also grade as Other in the HEMORRHAGE category.</p>					
CNS hemorrhage/bleeding	none	-	-	bleeding noted on CT or other scan with no clinical consequences	hemorrhagic stroke or hemorrhagic vascular event (CVA) with neurologic signs and symptoms
Epistaxis	none	mild without transfusion	-	requiring transfusion	catastrophic bleeding, requiring major non-elective intervention
Hematemesis	none	mild without transfusion	-	requiring transfusion	catastrophic bleeding, requiring major non-elective intervention
Hematuria (in the absence of vaginal bleeding)	none	microscopic only	intermittent gross bleeding, no clots	persistent gross bleeding or clots; may require catheterization or instrumentation, or transfusion	open surgery or necrosis or deep bladder ulceration
Hemoptysis	none	mild without transfusion	-	requiring transfusion	catastrophic bleeding, requiring major non-elective intervention
Hemorrhage/bleeding associated with surgery	none	mild without transfusion	-	requiring transfusion	catastrophic bleeding, requiring major non-elective intervention
<p>Note: Expected blood loss at the time of surgery is not graded as an adverse event.</p>					
Melena/GI bleeding	none	mild without transfusion	-	requiring transfusion	catastrophic bleeding, requiring major non-elective intervention
Petechiae/purpura (hemorrhage/bleeding into skin or mucosa)	none	rare petechiae of skin	petechiae or purpura in dependent areas of skin	generalized petechiae or purpura of skin or petechiae of any mucosal site	-

Adverse Event	Grade				
	0	1	2	3	4
Rectal bleeding/ hematochezia	none	mild without transfusion or medication	persistent, requiring medication (e.g., steroid suppositories) and/or break from radiation treatment	requiring transfusion	catastrophic bleeding, requiring major non- elective intervention
Vaginal bleeding	none	spotting, requiring <2 pads per day	requiring ≥2 pads per day, but not requiring transfusion	requiring transfusion	catastrophic bleeding, requiring major non- elective intervention
Hemorrhage - Other (Specify site, _____)	none	mild without transfusion	-	requiring transfusion	catastrophic bleeding, requiring major non- elective intervention
<b>HEPATIC</b>					
Alkaline phosphatase	WNL	>ULN - 2.5 x ULN	>2.5 - 5.0 x ULN	>5.0 - 20.0 x ULN	>20.0 x ULN
Bilirubin	WNL	>ULN - 1.5 x ULN	>1.5 - 3.0 x ULN	>3.0 - 10.0 x ULN	>10.0 x ULN
<b>Bilirubin associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol.</b>	<b>normal</b>	<b>≥2 - &lt;3 mg/100 mL</b>	<b>≥3 - &lt;6 mg/100 mL</b>	<b>≥6 - &lt;15 mg/100 mL</b>	<b>≥15 mg/100 mL</b>
GGT (γ - Glutamyl transpeptidase)	WNL	>ULN - 2.5 x ULN	>2.5 - 5.0 x ULN	>5.0 - 20.0 x ULN	>20.0 x ULN
<b>Hepatic enlargement</b>	<b>absent</b>	<b>-</b>	<b>-</b>	<b>present</b>	<b>-</b>
<b>Note: Grade Hepatic enlargement only for treatment related adverse event including Venous-Occlusive Disease.</b>					
Hypoalbuminemia	WNL	<LLN - 3 g/dL	≥2 - <3 g/dL	<2 g/dL	-
Liver dysfunction/ failure (clinical)	normal	-	-	asterixis	encephalopathy or coma
Portal vein flow	normal	-	decreased portal vein flow	reversal/retrograde portal vein flow	-
SGOT (AST) (serum glutamic oxaloacetic transaminase)	WNL	>ULN - 2.5 x ULN	>2.5 - 5.0 x ULN	>5.0 - 20.0 x ULN	>20.0 x ULN
SGPT (ALT) (serum glutamic pyruvic transaminase)	WNL	>ULN - 2.5 x ULN	>2.5 - 5.0 x ULN	>5.0 - 20.0 x ULN	>20.0 x ULN
Hepatic - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling
<b>INFECTION/FEBRILE NEUTROPENIA</b>					
Catheter-related infection	none	mild, no active treatment	moderate, localized infection, requiring local or oral treatment	severe, systemic infection, requiring IV antibiotic or antifungal treatment or hospitalization	life-threatening sepsis (e.g., septic shock)

Adverse Event	Grade				
	0	1	2	3	4
Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infection)  (ANC <1.0 x 10 <sup>9</sup> /L, fever ≥38.5°C)  Also consider Neutrophils.  Note: Hypothermia instead of fever may be associated with neutropenia and is graded here.	none	-	-	Present	Life-threatening sepsis (e.g., septic shock)
Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia  (ANC <1.0 x 10 <sup>9</sup> /L)  Also consider Neutrophils.  Notes: Hypothermia instead of fever may be associated with neutropenia and is graded here.  In the absence of documented infection grade 3 or 4 neutropenia with fever is graded as Febrile neutropenia.	none	-	-	present	life-threatening sepsis (e.g., septic shock)
Infection with unknown ANC  Note: This adverse event criterion is used in the rare case when ANC is unknown.	none	-	-	present	life-threatening sepsis (e.g., septic shock)
Infection without neutropenia  Also consider Neutrophils.	none	mild, no active treatment	moderate, localized infection, requiring local or oral treatment	severe, systemic infection, requiring IV antibiotic or antifungal treatment, or hospitalization	life-threatening sepsis (e.g., septic shock)
Wound-infectious is graded in the DERMATOLOGY/SKIN category.					
Infection/Febrile Neutropenia - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling
<b>LYMPHATICS</b>					
Lymphatics	normal	mild lymphedema	moderate lymphedema requiring compression; lymphocyst	severe lymphedema limiting function; lymphocyst requiring surgery	severe lymphedema limiting function with ulceration
Lymphatics - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling
<b>METABOLIC/LABORATORY</b>					
Acidosis (metabolic or respiratory)	normal	pH <normal, but ≥7.3	-	pH <7.3	pH <7.3 with life-threatening physiologic consequences
Alkalosis (metabolic or respiratory)	normal	pH >normal, but ≤7.5	-	pH >7.5	pH >7.5 with life-threatening physiologic consequences
Amylase	WNL	>ULN - 1.5 x ULN	>1.5 - 2.0 x ULN	>2.0 - 5.0 x ULN	>5.0 x ULN
Bicarbonate	WNL	<LLN - 16 mEq/dL	11 - 15 mEq/dL	8 - 10 mEq/dL	<8 mEq/dL



Adverse Event	Grade				
	0	1	2	3	4
CPK (creatine phosphokinase)	WNL	>ULN - 2.5 x ULN	>2.5 - 5 x ULN	>5 - 10 x ULN	>10 x ULN
Hypercalcemia	WNL	>ULN - 11.5 mg/dL >ULN - 2.9 mmol/L	>11.5 - 12.5 mg/dL >2.9 - 3.1 mmol/L	>12.5 - 13.5 mg/dL >3.1 - 3.4 mmol/L	>13.5 mg/dL >3.4 mmol/L
Hypercholesterolemia	WNL	>ULN - 300 mg/dL >ULN - 7.75 mmol/L	>300 - 400 mg/dL >7.75 - 10.34 mmol/L	>400 - 500 mg/dL >10.34 - 12.92 mmol/L	>500 mg/dL >12.92 mmol/L
Hyperglycemia	WNL	>ULN - 160 mg/dL >ULN - 8.9 mmol/L	>160 - 250 mg/dL >8.9 - 13.9 mmol/L	>250 - 500 mg/dL >13.9 - 27.8 mmol/L	>500 mg/dL >27.8 mmol/L or acidosis
Hyperkalemia	WNL	>ULN - 5.5 mmol/L	>5.5 - 6.0 mmol/L	>6.0 - 7.0 mmol/L	>7.0 mmol/L
Hypermagnesemia	WNL	>ULN - 3.0 mg/dL >ULN - 1.23 mmol/L	-	>3.0 - 8.0 mg/dL >1.23 - 3.30 mmol/L	>8.0 mg/dL >3.30 mmol/L
Hypernatremia	WNL	>ULN - 150 mmol/L	>150 - 155 mmol/L	>155 - 160 mmol/L	>160 mmol/L
Hypertriglyceridemia	WNL	>ULN - 2.5 x ULN	>2.5 - 5.0 x ULN	>5.0 - 10 x ULN	>10 x ULN
Hyperuricemia	WNL	>ULN - ≤10 mg/dL ≤0.59 mmol/L without physiologic consequences	-	>ULN - ≤10 mg/dL ≤0.59 mmol/L with physiologic consequences	>10 mg/dL >0.59 mmol/L
Also consider Tumor lysis syndrome, Renal failure, Creatinine, Hyperkalemia.					
Hypocalcemia	WNL	<LLN - 8.0 mg/dL <LLN - 2.0 mmol/L	7.0 - <8.0 mg/dL 1.75 - <2.0 mmol/L	6.0 - <7.0 mg/dL 1.5 - <1.75 mmol/L	<6.0 mg/dL <1.5 mmol/L
Hypoglycemia	WNL	<LLN - 55 mg/dL <LLN - 3.0 mmol/L	40 - <55 mg/dL 2.2 - <3.0 mmol/L	30 - <40 mg/dL 1.7 - <2.2 mmol/L	<30 mg/dL <1.7 mmol/L
Hypokalemia	WNL	<LLN - 3.0 mmol/L	-	2.5 - <3.0 mmol/L	<2.5 mmol/L
Hypomagnesemia	WNL	<LLN - 1.2 mg/dL <LLN - 0.5 mmol/L	0.9 - <1.2 mg/dL 0.4 - <0.5 mmol/L	0.7 - <0.9 mg/dL 0.3 - <0.4 mmol/L	<0.7 mg/dL <0.3 mmol/L
Hyponatremia	WNL	<LLN - 130 mmol/L	-	120 - <130 mmol/L	<120 mmol/L
Hypophosphatemia	WNL	<LLN -2.5 mg/dL <LLN - 0.8 mmol/L	≥2.0 - <2.5 mg/dL ≥0.6 - <0.8 mmol/L	≥1.0 - <2.0 mg/dL ≥0.3 - <0.6 mmol/L	<1.0 mg/dL <0.3 mmol/L
Hypothyroidism is graded in the ENDOCRINE category.					
Lipase	WNL	>ULN - 1.5 x ULN	>1.5 - 2.0 x ULN	>2.0 - 5.0 x ULN	>5.0 x ULN
Metabolic/Laboratory - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling
<b>MUSCULOSKELETAL</b>					
Arthralgia is graded in the PAIN category.					
Arthritis	none	mild pain with inflammation, erythema or joint swelling but not interfering with function	moderate pain with inflammation, erythema, or joint swelling interfering with function, but not interfering with activities of daily living	severe pain with inflammation, erythema, or joint swelling and interfering with activities of daily living	disabling

Adverse Event	Grade				
	0	1	2	3	4
Muscle weakness (not due to neuropathy)	normal	asymptomatic with weakness on physical exam	symptomatic and interfering with function, but not interfering with activities of daily living	symptomatic and interfering with activities of daily living	bedridden or disabling
Myalgia [tenderness or pain in muscles] is graded in the PAIN category.					
Myositis (inflammation/damage of muscle)	none	mild pain, not interfering with function	pain interfering with function, but not interfering with activities of daily living	pain interfering with function and interfering with activities of daily living	bedridden or disabling
Also consider CPK. Note: Myositis implies muscle damage (i.e., elevated CPK).					
Osteonecrosis (avascular necrosis)	none	asymptomatic and detected by imaging only	symptomatic and interfering with function, but not interfering with activities of daily living	symptomatic and interfering with activities of daily living	symptomatic; or disabling
Musculoskeletal - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling
<b>NEUROLOGY</b>					
Aphasia, receptive and/or expressive, is graded under Speech impairment in the NEUROLOGY category.					
Arachnoiditis/meningismus/radiculitis	absent	mild pain not interfering with function	moderate pain interfering with function, but not interfering with activities of daily living	severe pain interfering with activities of daily living	unable to function or perform activities of daily living; bedridden; paraplegia
Also consider Headache, Vomiting, Fever.					
Ataxia (incoordination)	normal	asymptomatic but abnormal on physical exam, and not interfering with function	mild symptoms interfering with function, but not interfering with activities of daily living	moderate symptoms interfering with activities of daily living	bedridden or disabling
CNS cerebrovascular ischemia	none	-	-	transient ischemic event or attack (TIA)	permanent event (e.g., cerebral vascular accident)
CNS hemorrhage/bleeding is graded in the HEMORRHAGE category.					
<i>Cognitive disturbance/learning problems</i>	<i>none</i>	<i>cognitive disability; not interfering with work/school performance; preservation of intelligence</i>	<i>cognitive disability; interfering with work/school performance; decline of 1 SD (Standard Deviation) or loss of developmental milestones</i>	<i>cognitive disability; resulting in significant impairment of work/school performance; cognitive decline &gt;2 SD</i>	<i>inability to work/frank mental retardation</i>

Adverse Event	Grade				
	0	1	2	3	4
Confusion	normal	confusion or disorientation or attention deficit of brief duration; resolves spontaneously with no sequelae	confusion or disorientation or attention deficit interfering with function, but not interfering with activities of daily living	confusion or delirium interfering with activities of daily living	harmful to others or self; requiring hospitalization
Cranial neuropathy is graded in the NEUROLOGY category as Neuropathy-cranial.					
Delusions	normal	-	-	present	toxic psychosis
Depressed level of consciousness	normal	somnolence or sedation not interfering with function	somnolence or sedation interfering with function, but not interfering with activities of daily living	obtundation or stupor; difficult to arouse; interfering with activities of daily living	coma
Note: Syncope (fainting) is graded in the NEUROLOGY category.					
Dizziness/lightheadedness	none	not interfering with function	interfering with function, but not interfering with activities of daily living	interfering with activities of daily living	bedridden or disabling
Dysphasia, receptive and/or expressive, is graded under Speech impairment in the NEUROLOGY category.					
Extrapyramidal/ involuntary movement/ restlessness	none	mild involuntary movements not interfering with function	moderate involuntary movements interfering with function, but not interfering with activities of daily living	severe involuntary movements or torticollis interfering with activities of daily living	bedridden or disabling
Hallucinations	normal	-	-	present	toxic psychosis
Headache is graded in the PAIN category.					
Insomnia	normal	occasional difficulty sleeping not interfering with function	difficulty sleeping interfering with function, but not interfering with activities of daily living	frequent difficulty sleeping, interfering with activities of daily living	-
Note: This adverse event is graded when insomnia is related to treatment. If pain or other symptoms interfere with sleep do NOT grade as insomnia.					
<b><i>Irritability (children &lt;3 years of age)</i></b>	<b><i>normal</i></b>	<b><i>mild; easily consolable</i></b>	<b><i>moderate; requiring increased attention</i></b>	<b><i>severe; inconsolable</i></b>	<b><i>-</i></b>
Leukoencephalopathy associated radiological findings	none	mild increase in SAS (subarachnoid space) and/or mild ventriculomegaly; and/or small (+/- multiple) focal T2 hyperintensities, involving periventricular white matter or <1/3 of susceptible areas of cerebrum	moderate increase in SAS; and/or moderate ventriculomegaly; and/or focal T2 hyperintensities extending into centrum ovale; or involving 1/3 to 2/3 of susceptible areas of cerebrum	severe increase in SAS; severe ventriculomegaly; near total white matter T2 hyperintensities or diffuse low attenuation (CT); focal white matter necrosis (cystic)	severe increase in SAS; severe ventriculomegaly; diffuse low attenuation with calcification (CT); diffuse white matter necrosis (MRI)
Memory loss	normal	memory loss not interfering with function	memory loss interfering with function, but not interfering with activities of daily living	memory loss interfering with activities of daily living	amnesia

Adverse Event	Grade				
	0	1	2	3	4
Mood alteration-anxiety, agitation	normal	mild mood alteration not interfering with function	moderate mood alteration interfering with function, but not interfering with activities of daily living	severe mood alteration interfering with activities of daily living	suicidal ideation or danger to self
Mood alteration-depression	normal	mild mood alteration not interfering with function	moderate mood alteration interfering with function, but not interfering with activities of daily living	severe mood alteration interfering with activities of daily living	suicidal ideation or danger to self
Mood alteration-euphoria	normal	mild mood alteration not interfering with function	moderate mood alteration interfering with function, but not interfering with activities of daily living	severe mood alteration interfering with activities of daily living	danger to self
Neuropathic pain is graded in the PAIN category.					
Neuropathy-cranial	absent	-	present, not interfering with activities of daily living	present, interfering with activities of daily living	life-threatening, disabling
Neuropathy-motor	normal	subjective weakness but no objective findings	mild objective weakness interfering with function, but not interfering with activities of daily living	objective weakness interfering with activities of daily living	paralysis
Neuropathy-sensory	normal	loss of deep tendon reflexes or paresthesia (including tingling) but not interfering with function	objective sensory loss or paresthesia (including tingling), interfering with function, but not interfering with activities of daily living	sensory loss or paresthesia interfering with activities of daily living	permanent sensory loss that interferes with function
Nystagmus	absent	present	-	-	-
Also consider Vision-double vision.					
Personality/behavioral	normal	change, but not disruptive to patient or family	disruptive to patient or family	disruptive to patient and family; requiring mental health intervention	harmful to others or self; requiring hospitalization
Pyramidal tract dysfunction (e.g., ↑ tone, hyperreflexia, positive Babinski, ↓ fine motor coordination)	normal	asymptomatic with abnormality on physical examination	symptomatic or interfering with function but not interfering with activities of daily living	interfering with activities of daily living	bedridden or disabling; paralysis
Seizure(s)	none	-	seizure(s) self-limited and consciousness is preserved	seizure(s) in which consciousness is altered	seizures of any type which are prolonged, repetitive, or difficult to control (e.g., status epilepticus, intractable epilepsy)
Speech impairment (e.g., dysphasia or aphasia)	normal	-	awareness of receptive or expressive dysphasia, not impairing ability to communicate	receptive or expressive dysphasia, impairing ability to communicate	inability to communicate
Syncope (fainting)	absent	-	-	present	-
Also consider CARDIOVASCULAR (ARRHYTHMIA), Vasovagal episode, CNS cerebrovascular ischemia.					

Adverse Event	Grade				
	0	1	2	3	4
Tremor	none	mild and brief or intermittent but not interfering with function	moderate tremor interfering with function, but not interfering with activities of daily living	severe tremor interfering with activities of daily living	-
Vertigo	none	not interfering with function	interfering with function, but not interfering with activities of daily living	interfering with activities of daily living	bedridden or disabling
Neurology - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling
<b>OCULAR/VISUAL</b>					
Cataract	none	asymptomatic	symptomatic, partial visual loss	symptomatic, visual loss requiring treatment or interfering with function	-
Conjunctivitis	none	abnormal ophthalmologic changes, but asymptomatic or symptomatic without visual impairment (i.e., pain and irritation)	symptomatic and interfering with function, but not interfering with activities of daily living	symptomatic and interfering with activities of daily living	-
Dry eye	normal	mild, not requiring treatment	moderate or requiring artificial tears	-	-
Glaucoma	none	increase in intraocular pressure but no visual loss	increase in intraocular pressure with retinal changes	visual impairment	unilateral or bilateral loss of vision (blindness)
Keratitis (corneal inflammation/ corneal ulceration)	none	abnormal ophthalmologic changes but asymptomatic or symptomatic without visual impairment (i.e., pain and irritation)	symptomatic and interfering with function, but not interfering with activities of daily living	symptomatic and interfering with activities of daily living	unilateral or bilateral loss of vision (blindness)
Tearing (watery eyes)	none	mild: not interfering with function	moderate: interfering with function, but not interfering with activities of daily living	interfering with activities of daily living	-
Vision-blurred vision	normal	-	symptomatic and interfering with function, but not interfering with activities of daily living	symptomatic and interfering with activities of daily living	-
Vision-double vision (diplopia)	normal	-	symptomatic and interfering with function, but not interfering with activities of daily living	symptomatic and interfering with activities of daily living	-
Vision-flashing lights/floaters	normal	mild, not interfering with function	symptomatic and interfering with function, but not interfering with activities of daily living	symptomatic and interfering with activities of daily living	-

Adverse Event	Grade				
	0	1	2	3	4
Vision-night blindness (nyctalopia)	normal	abnormal electro-retinography but asymptomatic	symptomatic and interfering with function, but not interfering with activities of daily living	symptomatic and interfering with activities of daily living	-
Vision-photophobia	normal	-	symptomatic and interfering with function, but not interfering with activities of daily living	symptomatic and interfering with activities of daily living	-
Ocular/Visual - Other (Specify, _____)	normal	mild	moderate	severe	unilateral or bilateral loss of vision (blindness)
<b>PAIN</b>					
Abdominal pain or cramping	none	mild pain not interfering with function	moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain: pain or analgesics severely interfering with activities of daily living	disabling
Arthralgia (joint pain)	none	mild pain not interfering with function	moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain: pain or analgesics severely interfering with activities of daily living	disabling
Arthritis (joint pain with clinical signs of inflammation) is graded in the MUSCULOSKELETAL category.					
Bone pain	none	mild pain not interfering with function	moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain: pain or analgesics severely interfering with activities of daily living	disabling
Chest pain (non-cardiac and non-pleuritic)	none	mild pain not interfering with function	moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain: pain or analgesics severely interfering with activities of daily living	disabling
Dysmenorrhea	none	mild pain not interfering with function	moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain: pain or analgesics severely interfering with activities of daily living	disabling
Dyspareunia	none	mild pain not interfering with function	moderate pain interfering with sexual activity	severe pain preventing sexual activity	-
Dysuria is graded in the RENAL/GENITOURINARY category.					
Earache (otalgia)	none	mild pain not interfering with function	moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain: pain or analgesics severely interfering with activities of daily living	disabling
Headache	none	mild pain not interfering with function	moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain: pain or analgesics severely interfering with activities of daily living	disabling

Adverse Event	Grade				
	0	1	2	3	4
Hepatic pain	none	mild pain not interfering with function	moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain: pain or analgesics severely interfering with activities of daily living	disabling
Myalgia (muscle pain)	none	mild pain not interfering with function	moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain: pain or analgesics severely interfering with activities of daily living	disabling
Neuropathic pain (e.g., jaw pain, neurologic pain, phantom limb pain, post-infectious neuralgia, or painful neuropathies)	none	mild pain not interfering with function	moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain: pain or analgesics severely interfering with activities of daily living	disabling
<b>Pain due to radiation</b>	<b>none</b>	<b>mild pain not interfering with function</b>	<b>moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living</b>	<b>severe pain: pain or analgesics severely interfering with activities of daily living</b>	<b>disabling</b>
Pelvic pain	none	mild pain not interfering with function	moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain: pain or analgesics severely interfering with activities of daily living	disabling
Pleuritic pain	none	mild pain not interfering with function	moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain: pain or analgesics severely interfering with activities of daily living	disabling
Rectal or perirectal pain (proctalgia)	none	mild pain not interfering with function	moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain: pain or analgesics severely interfering with activities of daily living	disabling
Tumor pain (onset or exacerbation of tumor pain due to treatment)	none	mild pain not interfering with function	moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain: pain or analgesics severely interfering with activities of daily living	disabling
Tumor flare is graded in the SYNDROME category.					
Pain - Other (Specify, _____)	none	mild	moderate	severe	disabling
<b>PULMONARY</b>					
Adult Respiratory Distress Syndrome (ARDS)	absent	-	-	-	present
Apnea	none	-	-	present	requiring intubation

Adverse Event	Grade				
	0	1	2	3	4
Carbon monoxide diffusion capacity (DL <sub>CO</sub> )	≥90% of pretreatment or normal value	≥75 - <90% of pretreatment or normal value	≥50 - <75% of pretreatment or normal value	≥25 - <50% of pretreatment or normal value	<25% of pretreatment or normal value
Cough	absent	mild, relieved by non-prescription medication	requiring narcotic antitussive	severe cough or coughing spasms, poorly controlled or unresponsive to treatment	-
Dyspnea (shortness of breath)	normal	-	dyspnea on exertion	dyspnea at normal level of activity	dyspnea at rest or requiring ventilator support
FEV <sub>1</sub>	≥90% of pretreatment or normal value	≥75 - <90% of pretreatment or normal value	≥50 - <75% of pretreatment or normal value	≥25 - <50% of pretreatment or normal value	<25% of pretreatment or normal value
Hiccoughs (hiccups, singultus)	none	mild, not requiring treatment	moderate, requiring treatment	severe, prolonged, and refractory to treatment	-
Hypoxia	normal	-	decreased O <sub>2</sub> saturation with exercise	decreased O <sub>2</sub> saturation at rest, requiring supplemental oxygen	decreased O <sub>2</sub> saturation, requiring pressure support (CPAP) or assisted ventilation
Pleural effusion (non-malignant)	none	asymptomatic and not requiring treatment	symptomatic, requiring diuretics	symptomatic, requiring O <sub>2</sub> or therapeutic thoracentesis	life-threatening (e.g., requiring intubation)
Pleuritic pain is graded in the PAIN category.					
Pneumonitis/pulmonary infiltrates	none	radiographic changes but asymptomatic or symptoms not requiring steroids	radiographic changes and requiring steroids or diuretics	radiographic changes and requiring oxygen	radiographic changes and requiring assisted ventilation
Pneumothorax	none	no intervention required	chest tube required	sclerosis or surgery required	life-threatening
Pulmonary embolism is graded as Thrombosis/embolism in the CARDIOVASCULAR (GENERAL) category.					
Pulmonary fibrosis	none	radiographic changes, but asymptomatic or symptoms not requiring steroids	requiring steroids or diuretics	requiring oxygen	requiring assisted ventilation
Note: Radiation-related pulmonary fibrosis is graded in the RTOG/EORTC Late Radiation Morbidity Scoring Scheme-Lung. (See Appendix IV)					
Voice changes/stridor/larynx (e.g., hoarseness, loss of voice, laryngitis)	normal	mild or intermittent hoarseness	persistent hoarseness, but able to vocalize; may have mild to moderate edema	whispered speech, not able to vocalize; may have marked edema	marked dyspnea/stridor requiring tracheostomy or intubation
Notes: Cough from radiation is graded as cough in the PULMONARY category. Radiation-related hemoptysis from larynx/pharynx is graded as Grade 4 Mucositis due to radiation in the GASTROINTESTINAL category. Radiation-related hemoptysis from the thoracic cavity is graded as Grade 4 Hemoptysis in the HEMORRHAGE category.					
Pulmonary - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling



Adverse Event	Grade				
	0	1	2	3	4
<b>RENAL/GENITOURINARY</b>					
Bladder spasms	absent	mild symptoms, not requiring intervention	symptoms requiring antispasmodic	severe symptoms requiring narcotic	-
Creatinine	WNL	>ULN - 1.5 x ULN	>1.5 - 3.0 x ULN	>3.0 - 6.0 x ULN	>6.0 x ULN
<i>Note: Adjust to age-appropriate levels for pediatric patients.</i>					
Dysuria (painful urination)	none	mild symptoms requiring no intervention	symptoms relieved with therapy	symptoms not relieved despite therapy	-
Fistula or GU fistula (e.g., vaginal, vesicovaginal)	none	-	-	requiring intervention	requiring surgery
Hemoglobinuria	-	present	-	-	-
Hematuria (in the absence of vaginal bleeding) is graded in the HEMORRHAGE category.					
Incontinence	none	with coughing, sneezing, etc.	spontaneous, some control	no control (in the absence of fistula)	-
Operative injury to bladder and/or ureter	none	-	injury of bladder with primary repair	sepsis, fistula, or obstruction requiring secondary surgery; loss of one kidney; injury requiring anastomosis or re-implantation	septic obstruction of both kidneys or vesicovaginal fistula requiring diversion
Proteinuria	normal or <0.15 g/24 hours	1+ or 0.15 - 1.0 g/24 hours	2+ to 3+ or 1.0 - 3.5 g/24 hours	4+ or >3.5 g/24 hours	nephrotic syndrome
<i>Note: If there is an inconsistency between absolute value and dip stick reading, use the absolute value for grading.</i>					
Renal failure	none	-	-	requiring dialysis, but reversible	requiring dialysis and irreversible
Ureteral obstruction	none	unilateral, not requiring surgery	-	bilateral, not requiring surgery	stent, nephrostomy tube, or surgery
Urinary electrolyte wasting (e.g., Fanconi's syndrome, renal tubular acidosis)	none	asymptomatic, not requiring treatment	mild, reversible and manageable with oral replacement	reversible but requiring IV replacement	irreversible, requiring continued replacement
<i>Also consider Acidosis, Bicarbonate, Hypocalcemia, Hypophosphatemia.</i>					
Urinary frequency/urgency	normal	increase in frequency or nocturia up to 2 x normal	increase >2 x normal but <hourly	hourly or more with urgency, or requiring catheter	-
Urinary retention	normal	hesitancy or dribbling, but no significant residual urine; retention occurring during the immediate postoperative period	hesitancy requiring medication or occasional in/out catheterization (<4 x per week), or operative bladder atony requiring indwelling catheter beyond immediate postoperative period but for <6 weeks	requiring frequent in/out catheterization (≥4 x per week) or urological intervention (e.g., TURP, suprapubic tube, urethrotomy)	bladder rupture

Adverse Event	Grade				
	0	1	2	3	4
Urine color change (not related to other dietary or physiologic cause e.g., bilirubin, concentrated urine, hematuria)	normal	asymptomatic, change in urine color	-	-	-
Vaginal bleeding is graded in the HEMORRHAGE category.					
Vaginitis (not due to infection)	none	mild, not requiring treatment	moderate, relieved with treatment	severe, not relieved with treatment, or ulceration not requiring surgery	ulceration requiring surgery
Renal/Genitourinary - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling
<b>SECONDARY MALIGNANCY</b>					
Secondary Malignancy - Other (Specify type, _____) excludes metastasis from initial primary	none	-	-	-	present
<b>SEXUAL/REPRODUCTIVE FUNCTION</b>					
Dyspareunia is graded in the PAIN category.					
Dysmenorrhea is graded in the PAIN category.					
Erectile impotence	normal	mild (erections impaired but satisfactory)	moderate (erections impaired, unsatisfactory for intercourse)	no erections	-
Female sterility	normal	-	-	sterile	-
Feminization of male is graded in the ENDOCRINE category.					
Irregular menses (change from baseline)	normal	occasionally irregular or lengthened interval, but continuing menstrual cycles	very irregular, but continuing menstrual cycles	persistent amenorrhea	-
Libido	normal	decrease in interest	severe loss of interest	-	-
Male infertility	-	-	oligospermia (low sperm count)	azoospermia (no sperm)	-
Masculinization of female is graded in the ENDOCRINE category.					
Vaginal dryness	normal	mild	requiring treatment and/or interfering with sexual function, dyspareunia	-	-
Sexual/Reproductive Function - Other (Specify, _____)	none	mild	moderate	severe	disabling
<b>SYNDROMES (not included in previous categories)</b>					
Acute vascular leak syndrome is graded in the CARDIOVASCULAR (GENERAL) category.					
ARDS (Adult Respiratory Distress Syndrome) is graded in the PULMONARY category.					

Adverse Event	Grade				
	0	1	2	3	4
Autoimmune reactions are graded in the ALLERGY/IMMUNOLOGY category.					
DIC (disseminated intravascular coagulation) is graded in the COAGULATION category.					
Fanconi's syndrome is graded as Urinary electrolyte wasting in the RENAL/GENITOURINARY category.					
Renal tubular acidosis is graded as Urinary electrolyte wasting in the RENAL/GENITOURINARY category.					
Stevens-Johnson syndrome (erythema multiforme) is graded in the DERMATOLOGY/SKIN category.					
SIADH (syndrome of inappropriate antidiuretic hormone) is graded in the ENDOCRINE category.					
Thrombotic microangiopathy (e.g., thrombotic thrombocytopenic purpura/TTP or hemolytic uremic syndrome/HUS) is graded in the COAGULATION category.					
Tumor flare	none	mild pain not interfering with function	moderate pain; pain or analgesics interfering with function, but not interfering with activities of daily living	severe pain; pain or analgesics interfering with function and interfering with activities of daily living	Disabling
Also consider Hypercalcemia.					
Note: Tumor flare is characterized by a constellation of symptoms and signs in direct relation to initiation of therapy (e.g., anti-estrogens/androgens or additional hormones). The symptoms/signs include tumor pain, inflammation of visible tumor, hypercalcemia, diffuse bone pain, and other electrolyte disturbances.					
Tumor lysis syndrome	absent	-	-	present	-
Also consider Hyperkalemia, Creatinine.					
Urinary electrolyte wasting (e.g., Fanconi's syndrome, renal tubular acidosis) is graded in the RENAL/GENITOURINARY category.					
Syndromes - Other (Specify, _____)	none	mild	moderate	severe	life-threatening or disabling

## Appendix I Adverse Event Module

To be implemented at the request of the study sponsor or principal investigator in the protocol or by protocol amendment when more detailed information is considered pertinent.

Adverse Event:	Date of Treatment:	Course Number:
Date of onset:		Grade at onset:
Date of first change in grade:		Grade:
Date of next change in grade:		Grade:
Date of next change in grade:		Grade:
Date of next change in grade:		Grade:
Date of next change in grade:		Grade:
Did adverse event resolve?                      Yes _____                      No _____		
If so, date of resolution of adverse event:		
Date of last observation (if prior to recovery):		
Reason(s) observations stopped (if prior to recovery):		
Was patient retreated?                      Yes _____                      No _____		
If yes, was treatment delayed for recovery?                      Yes _____                      No _____		
Date of next treatment?		
Dose reduced for next treatment?                      Yes _____                      No _____		

Additional Comments:

---



---

If module is being activated for new adverse event not currently in CTC, please provide definitions for adverse event grading:

Grade 0 = \_\_\_\_\_

Grade 1 = \_\_\_\_\_

Grade 2 = \_\_\_\_\_

Grade 3 = \_\_\_\_\_

Grade 4 = \_\_\_\_\_

## Appendix II Infection Module

To be implemented at the request of the study sponsor or principal investigator in the protocol or by protocol amendment when more detailed information is considered pertinent.

1. Use the Common Toxicity Criteria definitions to grade the severity of the infection.

1. Specify type of infection from the following (CHOOSE ONE):

BACTERIAL      FUNGAL      PROTOZOAL      VIRAL      UNKNOWN

1. Specify site of infection from the following (CHOOSE ALL THAT APPLY):

BLOOD CULTURE POSITIVE

BONE INFECTION

CATHETER (intravenous)

CATHETER (intravenous), tunnel infection

CENTRAL NERVOUS SYSTEM INFECTION

EAR INFECTION

EYE INFECTION

GASTROINTESTINAL INFECTION

ORAL INFECTION

PNEUMONIA

SKIN INFECTION

UPPER RESPIRATORY INFECTION

URINARY TRACT INFECTION

VAGINAL INFECTION

INFECTION, not otherwise specified (Specify site, \_\_\_\_\_)

1. Specify organism, if known: \_\_\_\_\_.

1. Prophylactic antibiotic, antifungal, or antiviral therapy administration

Yes \_\_\_\_\_ No \_\_\_\_\_

If prophylaxis was given prior to infection, please specify below:

Antibiotic prophylaxis \_\_\_\_\_

Antifungal prophylaxis \_\_\_\_\_

Antiviral prophylaxis \_\_\_\_\_

Other prophylaxis \_\_\_\_\_

## Appendix III

### Performance Status Scales/Scores

<b>PERFORMANCE STATUS CRITERIA</b>					
<i>Karnofsky and Lansky performance scores are intended to be multiples of 10.</i>					
ECOG (Zubrod)		Karnofsky		Lansky*	
Score	Description	Score	Description	Score	Description
<b>0</b>	<b>Fully active, able to carry on all pre-disease performance without restriction.</b>	<b>100</b>	<b>Normal, no complaints, no evidence of disease.</b>	<b>100</b>	<b>Fully active, normal.</b>
		<b>90</b>	<b>Able to carry on normal activity; minor signs or symptoms of disease.</b>	<b>90</b>	<b>Minor restrictions in physically strenuous activity.</b>
<b>1</b>	<b>Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work.</b>	<b>80</b>	<b>Normal activity with effort; some signs or symptoms of disease.</b>	<b>80</b>	<b>Active, but tires more quickly</b>
		<b>70</b>	<b>Cares for self, unable to carry on normal activity or do active work.</b>	<b>70</b>	<b>Both greater restriction of and less time spent in play activity.</b>
<b>2</b>	<b>Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.</b>	<b>60</b>	<b>Requires occasional assistance, but is able to care for most of his/her needs.</b>	<b>60</b>	<b>Up and around, but minimal active play; keeps busy with quieter activities.</b>
		<b>50</b>	<b>Requires considerable assistance and frequent medical care.</b>	<b>50</b>	<b>Gets dressed, but lies around much of the day; no active play; able to participate in all quiet play and activities.</b>
<b>3</b>	<b>Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.</b>	<b>40</b>	<b>Disabled, requires special care and assistance.</b>	<b>40</b>	<b>Mostly in bed; participates in quiet activities.</b>
		<b>30</b>	<b>Severely disabled, hospitalization indicated. Death not imminent.</b>	<b>30</b>	<b>In bed; needs assistance even for quiet play.</b>
<b>4</b>	<b>Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.</b>	<b>20</b>	<b>Very sick, hospitalization indicated. Death not imminent.</b>	<b>20</b>	<b>Often sleeping; play entirely limited to very passive activities.</b>
		<b>10</b>	<b>Moribund, fatal processes progressing rapidly.</b>	<b>10</b>	<b>No play; does not get out of bed.</b>

\*The conversion of the Lansky to ECOG scales is intended for NCI reporting purposes only.

## Appendix IV

### RTOG/EORTC Late Radiation Morbidity Scoring Scheme

Use for adverse event occurring greater than 90 days after radiation therapy.

Adverse Event	Grade				
	0	1	2	3	4
Bladder- Late RT Morbidity Scoring	No change from baseline	Slight epithelial atrophy/minor telangiectasia (microscopic hematuria)	Moderate frequency/generalized telangiectasia/intermittent macroscopic hematuria	Severe frequency and dysuria/severe generalized telangiectasia (often with petechiae); frequent hematuria; reduction in bladder capacity (<150 mL)	Necrosis/contracted bladder (capacity <100 mL)/severe hemorrhagic cystitis
Bone- Late RT Morbidity Scoring	No change from baseline	Asymptomatic; no growth retardation; reduced bone density	Moderate pain or tenderness; growth retardation; irregular bone sclerosis	Severe pain or tenderness; complete arrest of bone growth; dense bone sclerosis	Necrosis/spontaneous fracture
Brain- Late RT Morbidity Scoring	No change from baseline	Mild headache; slight lethargy	Moderate headache; great lethargy	Severe headaches; severe CNS dysfunction (partial loss of power or dyskinesia)	Seizures or paralysis; coma
Esophagus- Late RT Morbidity Scoring	No change from baseline	Mild fibrosis; slight difficulty in swallowing solids; no pain on swallowing	Unable to take solid food normally; swallowing semi-solid food; dilation may be indicated	Severe fibrosis; able to swallow only liquids; may have pain on swallowing; dilation required	Necrosis/perforation; fistula
Eye- Late RT Morbidity Scoring	No change from baseline	Asymptomatic cataract; minor corneal ulceration or keratitis	Symptomatic cataract; moderate corneal ulceration; minor retinopathy or glaucoma	Severe keratitis; severe retinopathy or detachment; severe glaucoma	Panophthalmitis; blindness
Heart- Late RT Morbidity Scoring	No change from baseline	Asymptomatic or mild symptoms; transient T wave inversion and ST changes; sinus tachycardia >110 (at rest)	Moderate angina on effort; mild pericarditis; normal heart size; persistent abnormal T wave and ST changes; low QRS	Severe angina; pericardial effusion; constrictive pericarditis; moderate heart failure; cardiac enlargement; EKG abnormalities	Tamponade/severe heart failure/severe constrictive pericarditis
Joint- Late RT Morbidity Scoring	No change from baseline	Mild joint stiffness; slight limitation of movement	Moderate stiffness; intermittent or moderate joint pain; moderate limitation of movement	Severe joint stiffness; pain with severe limitation of movement	Necrosis/complete fixation
Kidney- Late RT Morbidity Scoring	No change from baseline	Transient albuminuria; no hypertension; mild impairment of renal function; urea 25 - 35 mg%; creatinine 1.5 - 2.0 mg%; creatinine clearance >75%	Persistent moderate albuminuria (2+); mild hypertension; no related anemia; moderate impairment of renal function; urea >36 - 60 mg%; creatinine clearance >50 - 74%	Severe albuminuria; severe hypertension; persistent anemia (<10 g%); severe renal failure; urea >60 mg%; creatinine >4 mg%; creatinine clearance <50%	Malignant hypertension; uremic coma/urea >100%
Larynx- Late RT Morbidity Scoring	No change from baseline	Hoarseness; slight arytenoid edema	Moderate arytenoid edema; chondritis	Severe edema; severe chondritis	Necrosis

Appendix IV (continued)

RTOG/EORTC Late Radiation Morbidity Scoring Scheme

Use for adverse event occurring greater than 90 days after radiation therapy.

Adverse Event	Grade				
	0	1	2	3	4
Liver- Late RT Morbidity Scoring	No change from baseline	Mild lassitude; nausea; dyspepsia; slightly abnormal liver function	Moderate symptoms; some abnormal liver function tests; serum albumin normal	Disabling hepatic insufficiency; liver function tests grossly abnormal; low albumin; edema or ascites	Necrosis/hepatic coma or encephalopathy
Lung- Late RT Morbidity Scoring	No change from baseline	Asymptomatic or mild symptoms (dry cough); slight radiographic appearances	Moderate symptomatic fibrosis or pneumonitis (severe cough); low grade fever; patchy radiographic appearances	Severe symptomatic fibrosis or pneumonitis; dense radiographic changes	Severe respiratory insufficiency/continuous O <sub>2</sub> /assisted ventilation
Mucous membrane- Late RT Morbidity Scoring	No change from baseline	Slight atrophy and dryness	Moderate atrophy and telangiectasia; little mucus	Marked atrophy with complete dryness; severe telangiectasia	Ulceration
Salivary glands- Late RT Morbidity Scoring	No change from baseline	Slight dryness of mouth; good response on stimulation	Moderate dryness of mouth; poor response on stimulation	Complete dryness of mouth; no response on stimulation	Fibrosis
Skin- Late RT Morbidity Scoring	No change from baseline	Slight atrophy; pigmentation change; some hair loss	Patchy atrophy; moderate telangiectasia; total hair loss	Marked atrophy; gross telangiectasia	Ulceration
Small/Large intestine- Late RT Morbidity Scoring	No change from baseline	Mild diarrhea; mild cramping; bowel movement 5 x daily; slight rectal discharge or bleeding	Moderate diarrhea and colic; bowel movement >5 x daily; excessive rectal mucus or intermittent bleeding	Obstruction or bleeding, requiring surgery	Necrosis/perforation fistula
Spinal cord- Late RT Morbidity Scoring	No change from baseline	Mild Lhermitte's syndrome	Severe Lhermitte's syndrome	Objective neurological findings at or below cord level treatment	Mono-, para-, quadriplegia
Subcutaneous tissue- Late RT Morbidity Scoring	No change from baseline	Slight induration (fibrosis) and loss of subcutaneous fat	Moderate fibrosis but asymptomatic; slight field contracture; <10% linear reduction	Severe induration and loss of subcutaneous tissue; field contracture >10% linear measurement	Necrosis
Radiation - Other (Specify, _____)	None	Mild	Moderate	Severe	Life-threatening or disabling



## Appendix V

### BMT-Specific Adverse Events

Summary of BMT-Specific Adverse Events that may be used **if specified by the protocol**. These differ from the standard CTC and may be more relevant to the transplant setting. They are listed here for the convenience of investigators writing transplant protocols. They are also included in the CTC document.

Adverse Event	Grade				
	0	1	2	3	4
Bilirubin associated with graft versus host disease for BMT studies.	normal	≥2 - <3 mg/100 mL	≥3 - <6 mg/100 mL	≥6 - <15 mg/100 mL	≥15 mg/100 mL
Diarrhea associated with graft versus host disease (GVHD) for BMT studies.	none	>500 - ≤1000mL of diarrhea/day	>1000 - ≤1500mL of diarrhea/day	>1500mL of diarrhea/day	severe abdominal pain with or without ileus
<i>Diarrhea for pediatric BMT studies.</i>		<i>&gt;5 - ≤10 mL/kg of diarrhea/day</i>	<i>&gt;10 - ≤15 mL/kg of diarrhea/day</i>	<i>&gt;15 mL/kg of diarrhea/day</i>	-
Hepatic enlargement	absent	-	-	present	-
Leukocytes (total WBC) for BMT studies.	WNL	≥2.0 - <3.0 X 10 <sup>9</sup> /L ≥2000 - <3000/mm <sup>3</sup>	≥1.0 - <2.0 x 10 <sup>9</sup> /L ≥1000 - <2000/mm <sup>3</sup>	≥0.5 - <1.0 x 10 <sup>9</sup> /L ≥500 - <1000/mm <sup>3</sup>	<0.5 x 10 <sup>9</sup> /L <500/mm <sup>3</sup>
<i>Leukocytes (total WBC) for pediatric BMT studies (using age, race and sex normal values).</i>		<i>≥75 - &lt;100% LLN</i>	<i>≥50 - &lt;75% LLN</i>	<i>≥25 - 50% LLN</i>	<i>&lt;25% LLN</i>
<i>Lymphopenia for pediatric BMT studies (using age, race and sex normal values).</i>	mm <sup>3</sup>	<i>≥75-&lt;100%LLN</i>	<i>≥50-&lt;75%LLN</i>	<i>≥25-&lt;50%LLN</i>	<i>&lt;25%LLN</i>
Neutrophils/granulocytes (ANC/AGC) for BMT studies.	WNL	≥1.0 - <1.5 x 10 <sup>9</sup> /L ≥1000 - <1500/mm <sup>3</sup>	≥0.5 - <1.0 x 10 <sup>9</sup> /L ≥500 - <1000/mm <sup>3</sup>	≥0.1 - <0.5 x 10 <sup>9</sup> /L ≥100 - <500/mm <sup>3</sup>	<0.1 x 10 <sup>9</sup> /L <100/mm <sup>3</sup>
Platelets for BMT studies.	WNL	≥50.0 - <75.0 x 10 <sup>9</sup> /L ≥50,000 - <75,000/mm <sup>3</sup>	≥20.0 - <50.0 x 10 <sup>9</sup> /L ≥20,000 - <50,000/mm <sup>3</sup>	≥10.0 - <20.0 x 10 <sup>9</sup> /L ≥10,000 - <20,000/mm <sup>3</sup>	<10.0 x 10 <sup>9</sup> /L <10,000/mm <sup>3</sup>
Rash/dermatitis associated with high-dose chemotherapy or BMT studies.	none	faint erythema or dry desquamation	moderate to brisk erythema or a patchy moist desquamation, mostly confined to skin folds and creases; moderate edema	confluent moist desquamation, ≥1.5 cm diameter, not confined to skin folds; pitting edema	skin necrosis or ulceration of full thickness dermis; may include spontaneous bleeding not induced by minor trauma or abrasion
Rash/desquamation associated with graft versus host disease (GVHD) for BMT studies.	none	macular or papular eruption or erythema covering <25% of body surface area without associated symptoms	macular or papular eruption or erythema with pruritus or other associated symptoms covering ≥25 - <50% of body surface or localized desquamation or other lesions covering ≥25 - <50% of body surface area	symptomatic generalized erythroderma or symptomatic macular, papular or vesicular eruption, with bullous formation, or desquamation covering ≥50% of body surface area	generalized exfoliative dermatitis or ulcerative dermatitis or bullous formation

## Appendix V (Continued)

### BMT-Specific Adverse Events

Summary of BMT-Specific Adverse Events that may be used **if specified by the protocol**. These differ from the standard CTC and may be more relevant to the transplant setting. They are listed here for the convenience of investigators writing transplant protocols. They are also included in the CTC document.

Adverse Event	Grade				
	0	1	2	3	4
Stomatitis/pharyngitis (oral/pharyngeal mucositis) for BMT studies.	none	painless ulcers, erythema, or mild soreness in the absence of lesions	painful erythema, edema or ulcers but can swallow	painful erythema, edema, or ulcers preventing swallowing or requiring hydration or parenteral (or enteral) nutritional support	severe ulceration requiring prophylactic intubation or resulting in documented aspiration pneumonia
Transfusion: Platelets for BMT studies.	none	1 platelet transfusion in 24 hours	2 platelet transfusions in 24 hours	≥3 platelet transfusions in 24 hours	platelet transfusions and other measures required to improve platelet increment; platelet transfusion refractoriness associated with life-threatening bleeding. (e.g., HLA or cross matched platelet transfusions)
Transfusion: pRBCs for BMT studies.	none	≤2 u pRBC in 24 hours elective or planned	3 u pRBC in 24 hours elective or planned	≥4 u pRBC in 24 hours	hemorrhage or hemolysis associated with life-threatening anemia; medical intervention required to improve hemoglobin
<i>Transfusion: pRBCs for pediatric BMT studies.</i>	<i>none</i>	<i>≤15mL/kg in 24 hours elective or planned</i>	<i>&gt;15 - ≤30mL/kg in 24 hours elective or planned</i>	<i>&gt;30mL/kg in 24 hours</i>	<i>hemorrhage or hemolysis associated with life-threatening anemia; medical intervention required to improve hemoglobin</i>
Thrombotic microangiopathy (e.g., thrombotic thrombocytopenic purpura/TTP or hemolytic uremic syndrome/HUS) for BMT studies.	-	evidence of RBC destruction (schistocytosis) without clinical consequences	evidence of RBC destruction with elevated creatinine (≤3 x ULN)	evidence of RBC destruction with creatinine (>3 x ULN) not requiring dialysis	evidence of RBC destruction with renal failure requiring dialysis and/or encephalopathy
Weight gain associated with Venous-Occlusive Disease (VOD) for BMT studies.	<2%	≥2 - <5%	≥5 - <10%	≥10% or as ascites	≥10% or fluid retention resulting in pulmonary failure

## Appendix VI

### BMT Complex/Multicomponent Events

Adverse Event	Grade				
	0	1	2	3	4
Note: The grading of Complex/Multicomponent Events in bone marrow transplant will be defined in the protocol. The grading scale must use the CTC criteria for grading the specific component events (adverse events).					
Failure to engraft	absent	mild	moderate	severe	life-threatening
Also consider Hemoglobin, Neutrophils/granulocytes (ANC/AGC), Neutrophils/granulocytes (ANC/AGC) for BMT studies, if specified in the protocol, Platelets, Platelets for BMT studies, if specified in the protocol					
Graft versus host disease	absent	mild	moderate	severe	life-threatening
Also consider Fatigue, Rash/desquamation, Rash/desquamation associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol, Diarrhea for patients without colostomy, Diarrhea for patients with colostomy, Diarrhea associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol, Diarrhea for pediatric BMT studies, if specified in the protocol, Bilirubin, Bilirubin associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol					
Stem cell infusion complications	absent	mild	moderate	severe	life-threatening
Also consider Allergic reaction/hypersensitivity, Conduction abnormality/Atrioventricular heart block, Nodal/junctional arrhythmia/dysrhythmia, Prolonged QTc interval (QTc >0.48 seconds), Sinus bradycardia, Sinus tachycardia, Supraventricular arrhythmias (SVT/atrial fibrillation/flutter), Vasovagal episode, Ventricular arrhythmia (PVCs/bigeminy/trigeminy/ventricular tachycardia), Cardiovascular/Arrhythmia - Other (Specify, _____), Hypertension, Hypotension, Fever (in the absence of neutropenia, where neutropenia is defined as AGC <1.0 x 10 <sup>9</sup> /L), Rigors/chills, Sweating (diaphoresis), Rash/desquamation, Rash/desquamation associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol, Urticaria (hives, welts, wheals), Diarrhea for patients without colostomy, Diarrhea for patients with colostomy, Diarrhea associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol, Diarrhea for pediatric BMT studies, if specified in the protocol, Nausea, Vomiting, Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, Hemoptysis, Alkaline phosphatase, Bilirubin, Bilirubin associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol, GGT, SGOT (AST), SGPT (ALT), Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia (ANC <1.0 x 10 <sup>9</sup> /L), Infection without neutropenia, Hyperkalemia, Hyponatremia, Hypokalemia, Depressed level of consciousness, Seizures, Abdominal pain, Headache, Creatinine, Hemoglobinuria					
Veno-Occlusive Disease (VOD)	absent	mild	moderate	severe	life-threatening
Also consider Weight gain associated with Veno-Occlusive Disease (VOD) for BMT studies, if specified in the protocol, Bilirubin, Bilirubin associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol, Depressed level of consciousness, Hepatic pain, Renal failure, Hepatic enlargement					

" In revising the CTC, attention was directed to adverse events that occur with varying cancer therapies and patient populations. The CTC, v2.0 classifies adverse events that occur with investigational treatments including chemotherapy, biological therapy, radiation therapy, and surgery. For selected adverse events, different grading criteria are provided together for different patient populations. The adverse event name is the same; only the criteria for grading are changed. All special criteria are identified in bold text. For pediatrics and radiation therapy, these pertinent criteria should be used routinely." (CTC Manual, Item 2.2 Adverse Event Listing.)